Most recent update: Tuesday, July 16, 2019 - 19:15

Bariatric News - Cookies & privacy policy

You are here

DA intragastric balloons warning

ASGE/ABE issue response to FDA intragastric balloons warning

The AASGE and ABE has stated that any weight loss procedure, whether surgical or endoscopic, should not be entered into lightly.

The American Society for Gastrointestinal Endoscopy (ASGE) and the Association for Bariatric Endoscopy (ABE), a Division of ASGE, has responded to the FDA’s letter alerting healthcare providers about potential risks of liquid-filled intragastric balloon devices. The letter reported that seven deaths have occurred unexpectedly in patients with an implanted intragastric balloon since 2016.

Although not included in the FDA letter, these cases include patients treated with fluid-filled balloons both within and outside of the US. During US trials of the two-approved fluid-filled balloon devices currently in use, no deaths occurred. In its letter, the FDA noted that the agency has not been able to identify the root cause of mortality in these patients, and cannot attribute the cause to the devices or the procedure used to place them in the patient.

The ASGE and ABE has stated that any weight loss procedure, whether surgical or endoscopic, should not be entered into lightly. Patients are selected for these procedures based on their full medical history, and with extensive consideration given to all other methods for losing weight, including diet and lifestyle modifications.

Any weight loss procedure must be evaluated for its risks as well as benefits. Obesity comes with many serious effects that are important to modify through weight loss. For some patients, obesity is life threatening. This is why it is important to evaluate the total picture for patients with obesity.

In 2015, ASGE’s Bariatric Task Force published an analysis of data on the Orbera balloon, which was the only such device for which sufficient data was available at the time. This analysis found a mortality rate of .08 percent, or 8 in 10,000 patients. By their estimate, the new data from the FDA, looking at both Orbera and ReShape procedures, indicates a mortality rate of approximately .01 percent, or 1 in 10,000.

“Because we do not yet know the root cause in these cases, ASGE and ABE urge cautious interpretation and further investigation of the adverse event reports, and will be closely monitoring all information related to patient safety, including management of complications,” they said in a statement. “Our societies will continue to provide the best available information and education to our physician members on this topic. Patients should carefully consider the qualifications and training of any physician with whom they partner on medical procedures.”

ASGE and ABE added that they look forward to continuing to work with both the FDA and device manufacturers to ensure the best possible.

Want more stories like this? Subscribe to Bariatric News!

Bariatric News
Keep up to date! Get the latest news in your inbox. NOTE: Bariatric News WILL NOT pass on your details to 3rd parties. However, you may receive ‘marketing emails’ sent by us on behalf of 3rd parties.